Search Results - "Wind, Thijs T."

Value of screening and follow‐up brain MRI scans in patients with metastatic melanoma by Eggen, Annemarie C., Wind, Thijs T., Bosma, Ingeborg, Kramer, Miranda C. A., Laar, Peter Jan, Weide, Hiska L., Hospers, Geke A. P., Jalving, Mathilde

“…Background Novel treatments make long‐term survival possible for subsets of patients with melanoma brain metastases. Brain magnetic resonance imaging (MRI) may…”
Get full text

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma by Wind, Thijs T., Jalving, Mathilde, de Haan, Jacco J., de Vries, Elisabeth G. E., van Vugt, Marcel A. T. M., Reijngoud, Dirk-Jan, van Rijn, Rozemarijn S., Haanen, John B. A. G., Blank, Christian U., Hospers, Geke A. P., Fehrmann, Rudolf S. N.

“…This study aimed to establish the number of expression-based molecular subclasses in cutaneous melanoma, identify their dominant biological pathways and…”
Get full text

Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma by Wind, Thijs T., Gacesa, Ranko, Vich Vila, Arnau, de Haan, Jacco J., Jalving, Mathilde, Weersma, Rinse K., Hospers, Geke A.P.

“…In patients with metastatic cancer, gut microbiome composition differs between responder and non-responders to immune checkpoint inhibitors. However, there is…”
Get full text

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy by Boonstra, Pieter A., Wind, Thijs T., van Kruchten, Michel, Schuuring, Ed, Hospers, Geke A. P., van der Wekken, Anthonie J., de Groot, Derk-Jan, Schröder, Carolien P., Fehrmann, Rudolf S. N., Reyners, Anna K. L.

“…Response evaluation for cancer treatment consists primarily of clinical and radiological assessments. In addition, a limited number of serum biomarkers that…”
Get full text

Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy by van de Donk, Pim P., Wind, Thijs T., Hooiveld-Noeken, Jahlisa S., van der Veen, Elly L., Glaudemans, Andor W. J. M., Diepstra, Arjan, Jalving, Mathilde, de Vries, Elisabeth G. E., de Vries, Erik F. J., Hospers, Geke A. P.

“…Purpose Immune checkpoint inhibitors can induce a T cell–mediated anti-tumor immune response in patients with melanoma. Visualizing T cell activity using…”
Get full text

Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma by Björk, Johannes R., Bolte, Laura A., Maltez Thomas, Andrew, Lee, Karla A., Rossi, Niccolo, Wind, Thijs T., Smit, Lotte M., Armanini, Federica, Asnicar, Francesco, Blanco-Miguez, Aitor, Board, Ruth, Calbet-Llopart, Neus, Derosa, Lisa, Dhomen, Nathalie, Brooks, Kelly, Harland, Mark, Harries, Mark, Lorigan, Paul, Manghi, Paolo, Marais, Richard, Newton-Bishop, Julia, Nezi, Luigi, Pinto, Federica, Potrony, Miriam, Puig, Susana, Serra-Bellver, Patricio, Shaw, Heather M., Tamburini, Sabrina, Valpione, Sara, Waldron, Levi, Zitvogel, Laurence, Zolfo, Moreno, de Vries, Elisabeth G. E., Nathan, Paul, Fehrmann, Rudolf S. N., Spector, Tim D., Bataille, Véronique, Segata, Nicola, Hospers, Geke A. P., Weersma, Rinse K.

“…Multiple clinical trials targeting the gut microbiome are being conducted to optimize treatment outcomes for immune checkpoint blockade (ICB). To improve the…”
Get full text

Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program by Bisschop, Cornelis, Wind, Thijs T, Blank, Christian U, Koornstra, Rutger H T, Kapiteijn, Ellen, Van den Eertwegh, Alfonsus J M, De Groot, Jan Willem B, Jalving, Mathilde, Hospers, Geke A P

“…Toxicity of immune checkpoint inhibitors such as ipilimumab and nivolumab is likely associated with clinical efficacy. In this study, we aim to evaluate this…”
Get full text

89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake by Moek, Kirsten L., Waaijer, Stijn J.H., Kok, Iris C., Suurs, Frans V., Brouwers, Adrienne H., Menke-van der Houven van Oordt, C. Willemien, Wind, Thijs T., Gietema, Jourik A., Schröder, Carolien P., Mahesh, Shekar V.K., Jorritsma-Smit, Annelies, Lub-de Hooge, Marjolijn N., Fehrmann, Rudolf S.N., de Groot, Derk Jan A., de Vries, Elisabeth G.E.

“…Abstract Purpose: Biodistribution of bispecific antibodies in patients is largely unknown. We therefore performed a feasibility study in 9 patients with…”
Get full text

89 Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake by Moek, Kirsten L, Waaijer, Stijn J H, Kok, Iris C, Suurs, Frans V, Brouwers, Adrienne H, Menke-van der Houven van Oordt, C Willemien, Wind, Thijs T, Gietema, Jourik A, Schröder, Carolien P, Mahesh, Shekar V K, Jorritsma-Smit, Annelies, Lub-de Hooge, Marjolijn N, Fehrmann, Rudolf S N, de Groot, Derk Jan A, de Vries, Elisabeth G E

“…Biodistribution of bispecific antibodies in patients is largely unknown. We therefore performed a feasibility study in 9 patients with advanced…”
Get full text

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors by van Not, Olivier J, Wind, Thijs T, Ismail, Rawa K, Bhattacharya, Arkajyoti, Jalving, Mathilde, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, Haanen, John B, Kapiteijn, Ellen, Bloem, Manja, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Blokx, Willeke A M, Suijkerbuijk, Karijn P M, Fehrmann, Rudolf S N, Hospers, Geke A P

“…The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma that develop brain metastases (BM) remains unpredictable. In this study,…”
Get full text